Inventor · disambiguated record
Douglas Anthony Kerr
Also filed as: KERR DOUGLAS · KERR DOUGLAS A · KERR DOUGLAS ANTHONY
4 granted patents·17 pending applications·1 citations·filing 2006–2025
57Inventor score
Top patents by PatentIndex Score
21 records- 0162US2025282848A1Non-viral dna vectors and uses thereof for expressing fviii therapeuticsGENERATION BIO CO·Filed 2025·Application pending·0 cites
- 0258US12338275B2Non-viral DNA vectors and uses thereof for expressing FVIII therapeuticsGENERATION BIO CO·Filed 2020·Granted Jun 24, 2025·0 cites·17 claims
- 0356US2009155223A1Cell-based compositions and methods for treating conditions of the nervous systemUNIV JOHNS HOPKINS·Filed 2008·Application pending·0 cites
- 0455US2024181085A1Non-viral dna vectors and uses thereof for expressing pfic therapeuticsGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 0554US12415002B2Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeuticsGENERATION BIO CO·Filed 2020·Granted Sep 16, 2025·0 cites·21 claims
- 0654US2024226324A1Non-viral dna vectors expressing therapeutic antibodies and uses thereofGENERATION BIO CO·Filed 2022·Application pending·0 cites
- 0752US2023134550A1Non-viral dna vectors and uses thereof for expressing gaucher therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 0851US8986676B2MNTF differentiation and growth of stem cellsDESHPANDE DEEPA M·Filed 2006·Granted Mar 24, 2015·1 cites·22 claims
- 0950US2023383311A1Non-viral dna vectors and uses thereof for expressing fviii therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 1049US2024026374A1Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah)GENERATION BIO CO·Filed 2021·Application pending·0 cites
- 1148US2023138409A1Non-viral dna vectors and uses thereof for expressing factor ix therapeuticsGENERATION BIO CO·Filed 2021·Application pending·0 cites
- 1248US2022119840A1Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune responseGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 1346US2011123482A1Methods of Treating Neurological Autoimmune Disorders with CyclophosphamideUNIV JOHNS HOPKINS·Filed 2008·Application pending·0 cites
- 1446US2022228171A1Compositions and production of nicked closed-ended dna vectorsGENERATION BIO CO·Filed 2020·Application pending·0 cites
- 1544US2021059953A1Lipid nanoparticle formulations of non-viral, capsid-free dna vectorsGENERATION BIO CO·Filed 2018·Application pending·0 cites
- 1642US12442015B2Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectorsGENERATION BIO CO·Filed 2019·Granted Oct 14, 2025·0 cites·16 claims
- 1742US2020283794A1Modified closed-ended dna (cedna)GENERATION BIO CO·Filed 2018·Application pending·0 cites
- 1842US2022042035A1Non-viral dna vectors and uses thereof for antibody and fusion protein productionGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 1941US2022175970A1Controlled expression of transgenes using closed-ended dna (cedna) vectorsGENERATION BIO CO·Filed 2019·Application pending·0 cites
- 2041US2022290186A1Gene editing using a modified closed-ended dna (cedna)GENERATION BIO CO·Filed 2018·Application pending·0 cites
- 2131US2016101155A1Methods of treating neurological autoimmune disorders with cyclophosphamideUNIV JOHNS HOPKINS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Douglas Anthony Kerr files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →